171 related articles for article (PubMed ID: 35395077)
1. Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients.
Wang J; Kunzke T; Prade VM; Shen J; Buck A; Feuchtinger A; Haffner I; Luber B; Liu DHW; Langer R; Lordick F; Sun N; Walch A
Clin Cancer Res; 2022 Jul; 28(13):2865-2877. PubMed ID: 35395077
[TBL] [Abstract][Full Text] [Related]
2. Spatial metabolomics identifies distinct tumor-specific and stroma-specific subtypes in patients with lung squamous cell carcinoma.
Wang J; Sun N; Kunzke T; Shen J; Zens P; Prade VM; Feuchtinger A; Berezowska S; Walch A
NPJ Precis Oncol; 2023 Nov; 7(1):114. PubMed ID: 37919427
[TBL] [Abstract][Full Text] [Related]
3. Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer.
Wang J; Sun N; Kunzke T; Shen J; Feuchtinger A; Wang Q; Meixner R; Gleut RL; Haffner I; Luber B; Lordick F; Walch A
Br J Cancer; 2024 Apr; 130(6):1036-1045. PubMed ID: 38267634
[TBL] [Abstract][Full Text] [Related]
4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
5. Reproduction of the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) Gastric Cancer Molecular Classifications and Their Association with Clinicopathological Characteristics and Overall Survival in Moroccan Patients.
Nshizirungu JP; Bennis S; Mellouki I; Sekal M; Benajah DA; Lahmidani N; El Bouhaddouti H; Ibn Majdoub K; Ibrahimi SA; Celeiro SP; Viana-Pereira M; Munari FF; Ribeiro GG; Duval V; Santana I; Reis RM
Dis Markers; 2021; 2021():9980410. PubMed ID: 34367379
[TBL] [Abstract][Full Text] [Related]
6. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy.
Yuan Q; Deng D; Pan C; Ren J; Wei T; Wu Z; Zhang B; Li S; Yin P; Shang D
Front Immunol; 2022; 13():951137. PubMed ID: 35990657
[TBL] [Abstract][Full Text] [Related]
7. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
Matsushita D; Uenosono Y; Arigami T; Yanagita S; Okubo K; Kijima T; Miyazono F; Hamanoue M; Hokita S; Nakashima S; Ohtsuka T; Natsugoe S
Cancer Chemother Pharmacol; 2021 Jun; 87(6):789-797. PubMed ID: 33641065
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.
Wang HB; Liao XF; Zhang J
Medicine (Baltimore); 2017 Nov; 96(44):e8437. PubMed ID: 29095284
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of FOXP3 in gastric carcinoma; its relation to Ki-67 proliferation marker, HER2/neu expression, and other clinicopathological parameters.
Abd-Allah MYY; Abdel-Salam RA; Refat S
J Immunoassay Immunochem; 2022 Mar; 43(2):1959341. PubMed ID: 34806545
[TBL] [Abstract][Full Text] [Related]
12. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
Takahashi N; Furuta K; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y; Yamada Y
Oncotarget; 2016 Jan; 7(4):4925-38. PubMed ID: 26716644
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
[TBL] [Abstract][Full Text] [Related]
14. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
Haffner I; Schierle K; Raimúndez E; Geier B; Maier D; Hasenauer J; Luber B; Walch A; Kolbe K; Riera Knorrenschild J; Kretzschmar A; Rau B; Fischer von Weikersthal L; Ahlborn M; Siegler G; Fuxius S; Decker T; Wittekind C; Lordick F
J Clin Oncol; 2021 May; 39(13):1468-1478. PubMed ID: 33764808
[TBL] [Abstract][Full Text] [Related]
15. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
[TBL] [Abstract][Full Text] [Related]
16. Immunoexpression of PTEN, HER2/neu, and Ki-67 in endoscopic gastric carcinoma biopsies; their correlation with histological subtypes and one-year survival.
Acharya S; Thakur B; Mittal R
Indian J Pathol Microbiol; 2022; 65(1):29-34. PubMed ID: 35074962
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.
Lei YY; Huang JY; Zhao QR; Jiang N; Xu HM; Wang ZN; Li HQ; Zhang SB; Sun Z
World J Surg Oncol; 2017 Mar; 15(1):68. PubMed ID: 28327158
[TBL] [Abstract][Full Text] [Related]
19. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Pietrantonio F; Fucà G; Morano F; Gloghini A; Corso S; Aprile G; Perrone F; De Vita F; Tamborini E; Tomasello G; Gualeni AV; Ongaro E; Busico A; Giommoni E; Volpi CC; Laterza MM; Corallo S; Prisciandaro M; Antista M; Pellegrinelli A; Castagnoli L; Pupa SM; Pruneri G; de Braud F; Giordano S; Cremolini C; Di Bartolomeo M
Clin Cancer Res; 2018 Mar; 24(5):1082-1089. PubMed ID: 29208673
[No Abstract] [Full Text] [Related]
[Next] [New Search]
